BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 26628942)

  • 1. Clinicopathological and prognostic value of programmed death ligand-1 (PD-L1) in renal cell carcinoma: a meta-analysis.
    Xu F; Xu L; Wang Q; An G; Feng G; Liu F
    Int J Clin Exp Med; 2015; 8(9):14595-603. PubMed ID: 26628942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prevalence and prognostic and clinicopathological value of PD-L1 and PD-L2 in renal cell carcinoma patients: a systematic review and meta-analysis involving 3,389 patients.
    Lu Y; Song Y; Xu Y; Ou N; Liang Z; Hu R; Zhang W; Kang J; Wang X; Liu L; Yang Y; Liu X
    Transl Androl Urol; 2020 Apr; 9(2):367-381. PubMed ID: 32420142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic and Clinicopathological Value of Programmed Death Ligand-1 in Breast Cancer: A Meta-Analysis.
    Guo Y; Yu P; Liu Z; Maimaiti Y; Wang S; Yin X; Liu C; Huang T
    PLoS One; 2016; 11(5):e0156323. PubMed ID: 27227453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship of programmed death ligand-1 expression with clinicopathological features and prognosis in patients with oral squamous cell carcinoma: A meta-analysis.
    He J; Chen XF; Xu MG; Zhao J
    Arch Oral Biol; 2020 Jun; 114():104717. PubMed ID: 32344357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathologic Significance and Prognostic Value of Programmed Cell Death Ligand 1 (PD-L1) in Patients With Hepatocellular Carcinoma: A Meta-Analysis.
    Li JH; Ma WJ; Wang GG; Jiang X; Chen X; Wu L; Liu ZS; Zeng XT; Zhou FL; Yuan YF
    Front Immunol; 2018; 9():2077. PubMed ID: 30254644
    [No Abstract]   [Full Text] [Related]  

  • 6. Prognostic Value of Programmed Cell Death 1 Ligand-1 (PD-L1) or PD-1 Expression in Patients with Osteosarcoma: A Meta-Analysis.
    Huang X; Zhang W; Zhang Z; Shi D; Wu F; Zhong B; Shao Z
    J Cancer; 2018; 9(14):2525-2531. PubMed ID: 30026851
    [No Abstract]   [Full Text] [Related]  

  • 7. Prognostic and clinicopathological significance of PD-L1 in patients with renal cell carcinoma: a meta-analysis based on 1863 individuals.
    Wang Z; Peng S; Xie H; Guo L; Cai Q; Shang Z; Jiang N; Niu Y
    Clin Exp Med; 2018 May; 18(2):165-175. PubMed ID: 29362922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive Values of Programmed Cell Death-Ligand 1 Expression for Prognosis, Clinicopathological Factors, and Response to Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Inhibitors in Patients With Gynecological Cancers: A Meta-Analysis.
    Zhang C; Yang Q
    Front Oncol; 2020; 10():572203. PubMed ID: 33634012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic and Clinicopathological Significance of PD-L1 in Patients With Bladder Cancer: A Meta-Analysis.
    Zhu L; Sun J; Wang L; Li Z; Wang L; Li Z
    Front Pharmacol; 2019; 10():962. PubMed ID: 31616289
    [No Abstract]   [Full Text] [Related]  

  • 10. Prognostic and Clinicopathological Value of Programmed Cell Death Ligand1 Expression in Patients With Small Cell Lung Cancer: A Meta-Analysis.
    Cai H; Zhang H; Jiang Y
    Front Oncol; 2020; 10():1079. PubMed ID: 32670887
    [No Abstract]   [Full Text] [Related]  

  • 11. The Clinicopathologic and Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1) Expression in Patients With Prostate Cancer: A Systematic Review and Meta-Analysis.
    Li Y; Huang Q; Zhou Y; He M; Chen J; Gao Y; Wang X
    Front Pharmacol; 2018; 9():1494. PubMed ID: 30733677
    [No Abstract]   [Full Text] [Related]  

  • 12. The Clinicopathological and Prognostic Value of PD-L1 Expression in Cholangiocarcinoma: A Meta-Analysis.
    Xu G; Sun L; Li Y; Xie F; Zhou X; Yang H; Du S; Xu H; Mao Y
    Front Oncol; 2019; 9():897. PubMed ID: 31620360
    [No Abstract]   [Full Text] [Related]  

  • 13. Prognostic and clinicopathological value of PD-L1 in colorectal cancer: a systematic review and meta-analysis.
    Yang L; Xue R; Pan C
    Onco Targets Ther; 2019; 12():3671-3682. PubMed ID: 31190869
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinicopathological and prognostic significance of programmed cell death ligand 1 (PD-L1) expression in patients with esophageal squamous cell carcinoma: a meta-analysis.
    Qu HX; Zhao LP; Zhan SH; Geng CX; Xu L; Xin YN; Jiang XJ
    J Thorac Dis; 2016 Nov; 8(11):3197-3204. PubMed ID: 28066599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinicopathologic and Prognostic Significance of Programmed Cell Death Ligand 1 Expression in Patients with Non-Medullary Thyroid Cancer: A Systematic Review and Meta-Analysis.
    Aghajani M; Graham S; McCafferty C; Shaheed CA; Roberts T; DeSouza P; Yang T; Niles N
    Thyroid; 2018 Mar; 28(3):349-361. PubMed ID: 29455638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic role of PD-L1 expression in patients with salivary gland carcinoma: A systematic review and meta-analysis.
    Wu L; Jiang C; Zhu Z; Sun Y; Zhang T
    PLoS One; 2022; 17(7):e0272080. PubMed ID: 35881656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic Value of Programmed Cell Death 1 Ligand-1 in Patients With Bone and Soft Tissue Sarcomas: A Systemic and Comprehensive Meta-Analysis Based on 3,680 Patients.
    Wang F; Yu T; Ma C; Yuan H; Zhang H; Zhang Z
    Front Oncol; 2020; 10():749. PubMed ID: 32582532
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinicopathologic Significance and Prognostic Value of B7 Homolog 1 in Gastric Cancer: A Systematic Review and Meta-Analysis.
    Xu F; Feng G; Zhao H; Liu F; Xu L; Wang Q; An G
    Medicine (Baltimore); 2015 Oct; 94(43):e1911. PubMed ID: 26512615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of PD-L1 overexpression for pancreatic cancer: evidence from a meta-analysis.
    Zhuan-Sun Y; Huang F; Feng M; Zhao X; Chen W; Zhu Z; Zhang S
    Onco Targets Ther; 2017; 10():5005-5012. PubMed ID: 29081663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prognostic value of programmed cell death ligand 1 expression in non-Hodgkin lymphoma: a meta-analysis.
    Zhao S; Zhang M; Zhang Y; Meng H; Wang Y; Liu Y; Jing J; Huang L; Sun M; Zhang Y; Zhang Q
    Cancer Biol Med; 2018 Aug; 15(3):290-298. PubMed ID: 30197796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.